SCHEMBL5457889

SCHEMBL5457889

Cc1ccc([N+](=O)[O-])cc1NC(=O)Nc1sc2c(c1C(N)=O)CCOC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 1/20 0.55
▸ ANO1 Q5XXA6 2/20 0.47
▸ MAPT P10636 6/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ POLB P06746 3/20 0.46
▸ PDE4B Q07343 3/20 0.45
▸ MEN1 O00255 6/20 0.45
▸ KMT2A Q03164 6/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ GAA P10253 2/20 0.45
▸ BLM P54132 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ CCR6 P51684 1/20 0.44
▸ RAD52 P43351 1/20 0.44
▸ MCL1 Q07820 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ FLT3 P36888 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456038 0.88 FLT3 (0.56) CFTRMAPTALDH1A1POLBPDE4B
SCHEMBL5459139 0.87 CFTR (0.60) CFTRANO1MAPTALDH1A1MEN1
SCHEMBL5455890 0.86 CFTR (0.59) CFTRANO1SMN1; SMN2FLT3CNR1
SCHEMBL5447455 0.85 CFTR (0.58) CFTRANO1MAPTALDH1A1MEN1
SCHEMBL5457807 0.85 CFTR (0.55) CFTRANO1MEN1KMT2ANPC1
SCHEMBL5450630 0.84 MAPT (0.46) MAPTALDH1A1POLBPDE4BMEN1
SCHEMBL5451169 0.84 CFTR (0.55) CFTRANO1MAPTALDH1A1PDE4B
SCHEMBL5452660 0.83 PDE4B (0.53) CFTRMAPTPOLBPDE4BMEN1
SCHEMBL5457966 0.83 ANO1 (0.66) CFTRANO1MAPTMEN1KMT2A
SCHEMBL5458406 0.82 CFTR (0.55) CFTRANO1MAPTPDE4BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885ANO1 3245/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback